Rodger Currie to lead advocacy at US pharma trade body
pharmafile | February 3, 2016 | Appointment | Medical Communications | PhRMA, Pharmaceutical Research and Manufacturers of America
Rodger Currie has joined the Pharmaceutical Research and Manufacturers of America (PhRMA) association as executive vice president for advocacy.
He will lead federal, state and international government affairs and alliance development. Currie returned to PhRMA on February 1, 2016.
A recognised leader in government relations and health care, Currie has advocated on behalf of patient groups, physicians, hospitals and the life sciences industry. He most recently served as chief of government affairs at the American Psychiatric Association.
For more than a decade, he worked in the pharmaceutical industry: at Amgen as vice president of global government affairs, working for passage of the Biologics Price Competition and Innovation Act of 2009, which became law as part of the Affordable Care Act. He was also senior vice president for government affairs and law at PhRMA between 1998 and 2004, during the multi-year effort to pass and implement Medicare Part D.
“Rodger’s breadth of experience and proven track record of success will be an invaluable addition to the PhRMA team as we seek to improve patients’ access to care and foster the continued development of new treatments and cures for patients,” says Stephen Ubl, PhRMA president and chief executive.
Currie has a long record of working across party lines and collaborating with stakeholders across health care. For more than 10 consecutive years, The Hill newspaper named him a top lobbyist.
On his appointment he says: “The work of this industry is a passion of mine, and I’m excited to be coming home to PhRMA to help Steve Ubl bring the strongest possible advocacy for patients, innovation and cures. Steve brings energy and vision to the work we do and I am enthusiastic about joining his team”
“I look forward to working with PhRMA member companies and the broader health care community to create a climate that fosters investment in science and access to life-saving medicines.”
Related Content
US pharma lobby launches legal action against the Trump administration over drug pricing proposals
US industry organisations including the Pharmaceutical Research and Manufacturers of America (PhRMA) have launched legal …
Pharma boosts lobby spending in first quarter of 2019
The Pharmaceutical Research and Manufacturers of America (PhRMA) trade lobbyists have spent near record levels …
New hospital-led organisation aims to tackle drug pricing problem by manufacturing generic drugs
Seven organisations representing around 500 US hospitals have become the governing members of a newly …
